Labtician Ophthalmics announces commercial launch of artificial tear Lab TRIACTIV
Lab TRIACTIV is powered by “advanced cationic liposomal technology” for dry eye relief and targets all 3 layers of the tear film.
Image credit: AdobeStock/magraphics
Labtician Ophthalmics has announced the commercial launch of Lab TRIACTIV, an artificial tear designed to redefine dry eye relief.
Lab TRIACTIV is powered by “advanced cationic liposomal technology” and targets all 3 layers of the tear film (lipid, aqueous, and mucin) to provide “sustained hydration, enhanced protection, and long-lasting comfort with fewer daily applications.”
The company states that this artificial tear is designed to ensure a longer-lasting effect with fewer applications and that it is preservative-free and contact lens-compatible.
Polydor Strouthos, president of Labtician Ophthalmics commented on the launch in a press release from the company.
"We are incredibly proud to introduce Lab TRIACTIV to the Canadian market, reinforcing our commitment to advancing the Visual Health of Patients with solutions that make a real difference," said Strouthos. "Lab TRIACTIV supports our commitment to redefining industry standards. We are excited to set a new benchmark in dry eye care."
The company noted that the drops ingredients “optimize tear film stability and support ocular health.” These ingredients include stearylamine, cross-linked sodium hyaluronate, trehalose, and phospholipids.
References:
Labtician Ophthalmics, Inc. introduces Lab™TRIACTIV: The next evolution in dry eye management. Published March 27, 2025. Accessed March 27, 2025. https://www.newswire.ca/news-releases/labtician-ophthalmics-inc-introduces-lab-tm-triactiv-the-next-evolution-in-dry-eye-management-845525054.html
